Miglustat (NB-DNJ) works as a chaperone for mutated acid β-glucosidase in cells transfected with several Gaucher disease mutations
- 22 July 2005
- journal article
- Published by Elsevier
- Vol. 35 (2) , 268-276
- https://doi.org/10.1016/j.bcmd.2005.05.007
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The cell biology of lysosomal storage disordersNature Reviews Molecular Cell Biology, 2004
- Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapyJournal of Inherited Metabolic Disease, 2001
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Prospective study of neurological responses to treatment with macrophage‐targeted glucocerebrosidase in patients with type 3 Gaucher's diseaseAnnals of Neurology, 1997
- Expression of Mutated Glucocerebrosidase Alleles in Human CellsHuman Molecular Genetics, 1997
- Molecular chaperones in cellular protein foldingNature, 1996
- Folding intermediates are involved in genetic diseases?FEBS Letters, 1995
- The endoplasmic reticulum as a protein-folding compartmentTrends in Cell Biology, 1992
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- Expression of Functional Human Acid ß-Glucosidase in COS-1 and Spodoptera frugiperda CellsEnzyme, 1989